Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Glenmark Pharmaceuticals Limited ( (IN:GLENMARK) ) is now available.
Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Ltd., will launch Sodium Phosphates Injection USP in three single-dose vial strengths that are bioequivalent and therapeutically equivalent to Hospira Inc.’s reference product. Distribution is set to begin in April 2026, targeting a U.S. market that generated about $66.8 million in sales over the 12 months to December 2025.
The move deepens Glenmark’s presence in the institutional channel by adding another injectable to its U.S. hospital-focused portfolio, reinforcing its strategy of supplying quality, affordable alternatives to branded therapies. Management framed the launch as part of a broader push to expand its injectable offerings in North America, potentially enhancing its competitive position in the generic injectables segment and offering cost-effective options for healthcare providers and patients.
More about Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Ltd. is a global, research-led pharmaceutical company focused on innovation and accessibility, offering branded, innovative, generics and consumer health products. With 11 manufacturing facilities across four continents, six R&D centres and a commercial presence in more than 80 countries, it concentrates on respiratory, dermatology and oncology therapies and ranks among the top 100 biopharmaceutical companies by 2024 sales.
Average Trading Volume: 15,639
Technical Sentiment Signal: Strong Buy
Current Market Cap: 581.9B INR
For an in-depth examination of GLENMARK stock, go to TipRanks’ Overview page.